Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PedyPhar in Diabetic Foot Ulcers
NCT01531517Phase 3Terminated
- Sponsor
- European Egyptian Pharmaceutical Industries
- Start
- Jul 2011
- Primary completion
- Jul 2012
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of royal jelly + panthenol in diabetic foot ulcer (DFU) (2 arms), sponsored by European Egyptian Pharmaceutical Industries. Primary endpoint: Healing of the Ulcer at 5 months. Started Jul 2011; status: terminated.
02
Drugs
royal jelly + panthenol
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT01531517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01531517.